Skip to main content
. 2024 Feb 29;10(5):e27196. doi: 10.1016/j.heliyon.2024.e27196

Fig. 2.

Fig. 2

CAR-NK cells: growing interest and data from preclinical and clinical studies. (A) Bar graph showing the number of manuscripts reporting experimental data on human CAR-NK cells until August 2022. (B) Bars show the number of publications in all CAR-NK cells derived from NK-92MI cell lines (blue) and primary NK cells (yellow). (C) Pie charts showing the percentage of publications in different countries. (D) Pie charts showing the percentage of publications in different generations. (E) Bars show the number of CAR-NK clinical trials in all patients with CAR-NK cells derived from solid tumors (yellow) and hematologic tumors (pink). (F) Pie charts showing the percentage of CAR-NK clinical trials in different countries.